Although TNFα inhibitors have improved the quality of life of many patients with autoimmune diseases, a significant proportion of patients remain in a progressive disease state and poor quality of life due to the failure of anti-TNFα therapy. The gene discussed is TNF; the disease is autoimmune disease.